15-7-5 ⓔ文献
Brodeur GM, Pritchard J, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol, 1993; 11: 1466–1477.
Shimada H, Umehara S, et al: International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer. 2001; 92: 2451–2461.
Ambros IM, Hata J, et al: Morphologic features of neuroblastoma (Schwannian stroma–poor tumors) in clinically favorable and unfavorable groups. Cancer, 2002; 94: 1574–1583.
Mossé YP, Laudenslager M, et al: Identification of ALK as a major familial neuroblastoma predisposition gene. Nature, 2008; 455: 930–935.
Pugh TJ, Morozova O, et al: The genetic landscape of high–risk neuroblastoma. Nat Genet, 2013; 45: 279–284.
London WB, Castleberry RP, et al: Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol, 2005; 23: 6459–6465.
Park JR, Eggert A, et al: Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am, 2010; 24: 65–86.
Matthay KK, Blaes F, et al: Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett, 2005; 228: 275–282.
日本小児血液・がん学会編：神経芽腫．小児がん診療ガイドライン2016年版，金原出版，2016; 199–249．